EUVIMEDEUVIMED entdecken
Crossref

A TiVCrMoC3 MXene-Based Sustained-Release Vancomycin Nanoplatform Mitigates Septic Arthritis through Modulation of Bacterial Acetate Metabolism

Xi Yu, Xinfeng Yan, Chenyang Bai, Chunxia Ma iD, Qing He, Zhilong Chu, Shuwen Liu, Ge Fang, Hao Zhang, Weiqiang Liang iD

ACS Applied Materials & Interfaces · 11.11.2026 · 18 (44) · 60496-60515

DOI: 10.1021/acsami.6c14214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 02.11.2026. Verfasst von Xi Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Shandong First Medical University, Shandong First Medical University, Jinan250014, China. Hauptthemen laut MEDLINE: Vancomycin, Arthritis, Infectious, Anti-Bacterial Agents, Staphylococcus aureus. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Provincial Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute septic arthritis caused by bacterial infection is a common and serious orthopedic disease. The formation of bacterial biofilms severely limits antibiotic penetration, rendering conventional therapy ineffective and short‑acting. In this study, we developed a novel nanodrug delivery system by loading vancomycin onto high‑entropy TiVCrMoC3 MXene (VCM@NPs). Featuring a sheet‑like porous structure, this material enables efficient drug loading via electrostatic interactions and sustains release in the weakly acidic infection microenvironment, achieving a cumulative release of 67% over 20 days. In vitro, VCM@NPs exhibited potent bactericidal activity against Staphylococcus aureus, with complete colony eradication by day 5, and markedly disrupted biofilm architecture, as shown by electron and confocal microscopy. In a rat septic arthritis model, a single intra‑articular injection of VCM@NPs effectively inhibited bacterial growth, alleviated joint inflammation, and improved cartilage and bone damage. By day 10, OARSI scores in the VCM@NPs group were significantly lower than those in the free vancomycin group, and micro‑CT analysis revealed increased bone volume and trabecular thickness, confirming sustained therapeutic efficacy. Notably, mass spectrometry imaging demonstrated that VCM@NPs reprogrammed the joint metabolic microenvironment by suppressing the bacterial acetate metabolic pathway, thereby destabilizing biofilms—a mechanism that, to the best of our knowledge, has not been previously reported in the context of nanoparticle-mediated modulation of this pathway. Collectively, this study offers a new nanodrug delivery strategy that integrates sustained release with biofilm disruption, holding promise for clinical translation in septic arthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinArthritis, InfectiousAnti-Bacterial AgentsStaphylococcus aureusAcetatesNanoparticlesAnimalsRatsBiofilmsDelayed-Action PreparationsRats, Sprague-DawleyStaphylococcal InfectionsMaleNitritesTransition Elements

Stichwörter der Autor:innen

Staphylococcus aureusdrug-loaded nanoparticlesmass spectrometry imagingseptic arthritisvancomycin

Substanzen

VancomycinAnti-Bacterial AgentsDelayed-Action PreparationsAcetatesMXeneNitritesTransition Elements

Autor:innen und Institutionen

  • The First Affiliated Hospital of Shandong First Medical University, Shandong First Medical University, Jinan250014, China.
  • Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan250014, China.
  • Shandong Experimental High School, Jinan250001, China.
  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai200032, China.
  • Department of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200025, China.
  • School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan250012, China.

ORCID-Profile: Chunxia Ma, Weiqiang Liang

Förderung

  • National Natural Science Foundation of China
  • Shandong Provincial Medical Association

Zitieren

APA

Yu, X., Yan, X., Bai, C., Ma, C., He, Q., Chu, Z., Liu, S., Fang, G., Zhang, H., & Liang, W. (2026). A TiVCrMoC3 MXene-Based Sustained-Release Vancomycin Nanoplatform Mitigates Septic Arthritis through Modulation of Bacterial Acetate Metabolism. ACS Applied Materials & Interfaces, 18(44), 60496-60515. https://doi.org/10.1021/acsami.6c14214

Vancouver

Yu X, Yan X, Bai C, Ma C, He Q, Chu Z, et al. A TiVCrMoC3 MXene-Based Sustained-Release Vancomycin Nanoplatform Mitigates Septic Arthritis through Modulation of Bacterial Acetate Metabolism. ACS Applied Materials & Interfaces. 2026;18(44):60496-60515. doi:10.1021/acsami.6c14214

BibTeX
@article{Yu2026,
  author = {Yu, Xi and Yan, Xinfeng and Bai, Chenyang and Ma, Chunxia and He, Qing and Chu, Zhilong and Liu, Shuwen and Fang, Ge and Zhang, Hao and Liang, Weiqiang},
  title = {A TiVCrMoC3 MXene-Based Sustained-Release Vancomycin Nanoplatform Mitigates Septic Arthritis through Modulation of Bacterial Acetate Metabolism},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  volume = {18},
  number = {44},
  pages = {60496--60515},
  doi = {10.1021/acsami.6c14214}
}
Kostenlos starten →